WALTHAM, MA -- August 7, 2007 -- PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, today announced a new introductory configuration for its leading Opera™ High Content Screening (HCS) system. The new Opera LX is specifically designed for researchers who need the power of high throughput confocal imaging for their drug discovery and academic research, but in a scalable configuration that can expand as their screening needs increase.

PerkinElmer’s full-scale Opera QEHS system is the premier confocal microplate imaging reader on the market, delivering fully automated, high speed and high resolution imaging for primary and secondary cellular screening in the drug discovery, systems biology, and safety pharmacology markets. These systems are proving essential to important research efforts in oncology, neuroscience, in vitro toxicology, immunology, and cardiovascular medicine, among other areas.

“Researchers in both the academic and pharmaceutical markets are increasingly adopting a cell-based approach to their drug discovery research, shifting their focus away from biochemical analysis of discrete cellular components to evaluate cellular function, including tissue and organ activity, through live cell imaging,” said Robert Friel, President and Chief Operating Officer for PerkinElmer, Inc. “The Opera system is the gold standard HCS reader providing unrivaled resolution and speed as well as powerful, intuitive Acapella™ software to provide better insight into the data collected. With the Opera LX, researchers can access the power of HCS at an introductory system price-range with the option to upgrade to full-scale capability.”

The Opera LX can be custom configured with a laser combination of choice and can be equipped with a number of options, such as an environmental control unit, lenses, UV light source including second camera for parallel image acquisition, liquid handling, plate handling / storage and incubation. All accessory units can be field upgraded thus enabling a user to start with a basic configuration for assay development and small-to-medium throughput campaigns for a variety of applications that can be gradually upgraded to the Opera QEHS that includes all options and full high throughput live cell screening capacity.

The accompanying Acapella image analysis software with Cellular Assay Library is a powerful, intuitive system that allows for quick training of new users, but also offers full flexibility in algorithm development for the power user.

The Opera LX expands PerkinElmer’s comprehensive drug discovery instrumentation and reagents portfolio, further demonstrating the company’s commitment to providing high-performance live cell imaging technologies to meet the needs and budgets of researchers throughout the life sciences.

For more product information on the Opera system or other PerkinElmer drug discovery and research technologies, visit PerkinElmer online at: www.perkinelmer.com or contact your sales representative.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.